Peripheral Protective Sensation in Type 2 Diabetes Mellitus
The Effect of Peripheral Protective Sensation on Peripheral Muscle Strength, Functional Capacity, Balance and Physical Activity Level in Patients With Type 2 Diabetes Mellitus
1 other identifier
observational
42
1 country
1
Brief Summary
The aim of our study was to investigate the effect of sole sensation on peripheral muscle strength, functional capacity, balance and physical activity level in individuals with Type 2 Diabetes Mellitus.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 24, 2023
CompletedStudy Start
First participant enrolled
June 6, 2023
CompletedFirst Posted
Study publicly available on registry
June 15, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 25, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 25, 2023
CompletedJuly 27, 2023
July 1, 2023
19 days
May 24, 2023
July 25, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Foot Sole Sensation Evaluation
Light touch pressure sensation will be assessed with the 10-g monofilament -Semmes Weinstein test. A 128 Hz diapause will be used to test the sense of vibration. Firstly, the diaposon will be applied to the patient's wrist (it can be on the elbow or clavicle), so that the patient will know what to experience beforehand. The diapozone is placed on the bone on the dorsal side of the distal phalanx of the first toe of the foot.For two-point discrimination sensation, two-point discrimination distance measurement with an esthesiometer (Baseline® , White Plains, NY, USA) will be used
20 minute
Secondary Outcomes (7)
Body mass index
5 minute
Body Fat
5 minute
Skeletal muscle mass
5 minute
Resting metabolism
5 minute
Balance
20 minute
- +2 more secondary outcomes
Study Arms (1)
Type 2 diabetic patients
Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
Interventions
Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
Eligibility Criteria
Patients who were followed up with the diagnosis of Diabetes Mellitus at the Internal Medicine Outpatient Clinic of the Eyup Additional Service Building of Bezmialem October Foundation University
You may qualify if:
- Being diagnosed with Type 2 Diabetes Mellitus for at least 1 year
- To be between the ages of 18-65
- HbA1c value between 6.5-11
- No cognitive/mental problems
- Being able to walk independently
- Being literate in Turkish
You may not qualify if:
- Lack of co-operation
- Patients with uncontrolled hypertension and uncontrolled arrhythmias
- Vertigo and various vestibular system disorders
- Those with severe neurological or severe respiratory diseases
- Patients who have undergone percutaneous transluminal coronary angiography or have a cardiac pacemaker
- Previous stroke, myocardial infarction
- Patients with major musculoskeletal problems
- Chronic renal failure
- Chronic liver disease
- Patients with hip or knee replacement surgery in the last 5 years
- Patients with an injury involving the lower extremity in the last 6 months
- Those who are pregnant
- Those with haemolytic or renal anaemia
- Those who cannot read and write Turkish
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Istanbul Kent Universitylead
- Bezmialem Vakif Universitycollaborator
Study Sites (1)
Bezmialem Vakıf Unıversty
Istanbul, 340060, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Reserach Assistant
Study Record Dates
First Submitted
May 24, 2023
First Posted
June 15, 2023
Study Start
June 6, 2023
Primary Completion
June 25, 2023
Study Completion
July 25, 2023
Last Updated
July 27, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will not share